Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on May 1st and 2nd, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of company stock.
• The transactions occurred on May 1, 2025, and May 2, 2025.
• A total of 5,030 shares were sold on May 1 at a weighted average price of $20.0728, with prices ranging from $20.00 to $20.14.
• On May 2, 2,470 shares were sold at a weighted average price of $20.0099, with prices ranging from $20.00 to $20.045.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following these transactions, Lyssikatos indirectly owns 990,188 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions. The use of a 10b5-1 plan suggests pre-planned sales, which is neutral.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, although these sales were conducted under a pre-arranged trading plan.

Industry Context

Insider sales are a common occurrence in publicly traded companies, and the use of Rule 10b5-1 trading plans allows insiders to sell shares over time while avoiding concerns about trading on non-public information.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Enliven Therapeutics, ELVN, insider trading, Form 4, stock sale, Rule 10b5-1, Joseph P. Lyssikatos, Chief Scientific Officer